10061626Probing the molecular interactions within carrier nanopores to enable model validation and deploymentClosedCollaborative R&DInnovate UKMESOX developed a novel particle carrier technology for enhancing the bioavailability of medicines. The carrier has nanopores within its structure and each nanopore behaves like a nano-container for drug molecules. When a drug is loaded within a nanopore, it converts to its amorphous solid form which easily dissolves in the patient body. As a result, drug efficacy could be enhanced due to better absorption, and lower doses would be required as opposed to the drug in its native state without our carrier. In line with the developed carrier, we have also built a molecular model of the carrier which allows us to screen drugs virtually on a computer prior to conducting laboratory experiments. This provides two key advantages to potential pharma and biotech customers: 1- Saves their precious drug through avoiding extensive experimental formulation work. 2- Provides quick feedback on the feasibility of our carrier technology for their drug molecule. However, a key to unlocking the power of this molecular model is to validate its observations using an advanced analytical technique. A technique is needed that can quantify the amount of drug within carrier (maximum amount that can be loaded), nature of drug loaded within carrier (molecular interactions, amorphous/crystalline phase) and preserves the carrier structure during the analysis process (for reliable results). The national physical laboratory will assist us with an advanced analytical technique that meets the above criteria for model validation. Our modelling capability once validated will represent a leap forward in formulation development science. It will help reduce the risks of the formulation process leading to lower product costs, and accelerate the timelines for the development of new medicines. Ultimately, this approach could lead to more lifesaving medicines getting into patients' hands quicker and saving the NHS and the UK taxpayer millions of pounds in healthcare costs.